Patents by Inventor Krisztina Pongracz

Krisztina Pongracz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11279720
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: March 22, 2022
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Publication number: 20200377543
    Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.
    Type: Application
    Filed: July 31, 2020
    Publication date: December 3, 2020
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
  • Publication number: 20200283461
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 10, 2020
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 10738073
    Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 11, 2020
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
  • Patent number: 10655127
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 19, 2020
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Patent number: 10562926
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 18, 2020
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 10494398
    Abstract: This invention relates to antisense oligonucleotides comprising at least one N3??P5? phosphorodiamidate linkage (NPN) in the backbone, useful for modulating gene expression involved in the pathogenesis of a disease. Compounds useful as building blocks of said antisense oligonucleotides and methods of preparing building block compounds including NPN linkages are provided.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: December 3, 2019
    Assignee: Geron Corporation
    Inventors: Krisztina Pongracz, Mahesh Ramaseshan
  • Publication number: 20190106447
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: June 22, 2018
    Publication date: April 11, 2019
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 10196641
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: February 5, 2019
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20190031707
    Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 31, 2019
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
  • Patent number: 10035815
    Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: July 31, 2018
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
  • Patent number: 10035814
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: July 31, 2018
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Publication number: 20180119147
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Application
    Filed: October 18, 2017
    Publication date: May 3, 2018
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20180002367
    Abstract: This invention relates to antisense oligonucleotides comprising at least one N3??P5? phosphorodiamidate linkage (NPN) in the backbone as well as methods for using the same. The antisense oligonucleotides can effectively prevent or decrease protein expression.
    Type: Application
    Filed: June 7, 2017
    Publication date: January 4, 2018
    Inventors: Krisztina PONGRACZ, Mahesh Ramaseshan
  • Patent number: 9822360
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: November 21, 2017
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20170233419
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: January 30, 2017
    Publication date: August 17, 2017
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 9708360
    Abstract: This invention relates to antisense oligonucleotides comprising at least one N3??P5? phosphorodiamidate linkage (NPN) in the backbone, and kits and pharmaceutical compositions thereof, useful for modulating gene expression involved in the pathogenesis of a disease. Also included are compounds useful as building blocks of said antisense oligonucleotides and methods of preparing said antisense oligonucleotides and building block compounds including NPN linkages.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: July 18, 2017
    Assignee: Geron Corporation
    Inventors: Krisztina Pongracz, Mahesh Ramaseshan
  • Patent number: 9657296
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 23, 2017
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20170130225
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Application
    Filed: June 27, 2016
    Publication date: May 11, 2017
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Patent number: 9593137
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are useful in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 14, 2017
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz